Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?

Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	M. Rossini [verfasserIn] O Viapiana [verfasserIn] G. Orsolini [verfasserIn] E. Fracassi [verfasserIn] L. Idolazzi [verfasserIn] D. Gatti [verfasserIn] S. Adami [verfasserIn] M. Govoni [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch ; Italienisch

Erschienen:	2015

Schlagwörter:	Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis.

Übergeordnetes Werk:	In: Reumatismo - PAGEPress Publications, 2012, 66(2015), 4, Seite 285-303
Übergeordnetes Werk:	volume:66 ; year:2015 ; number:4 ; pages:285-303

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.4081/reumatismo.2014.799

Katalog-ID:	DOAJ043830323

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ043830323
003	DE-627
005	20230308074401.0
007	cr uuu---uuuuu
008	230227s2015 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.4081/reumatismo.2014.799 \|2 doi
035			\|a (DE-627)DOAJ043830323
035			\|a (DE-599)DOAJ8d70cd031672426885f9e3dce692b8ee
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng \|a ita
050		0	\|a RC31-1245
100	0		\|a M. Rossini \|e verfasserin \|4 aut
245	1	0	\|a Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
264		1	\|c 2015
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.
650		4	\|a Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis.
653		0	\|a Medicine
653		0	\|a R
653		0	\|a Internal medicine
700	0		\|a O Viapiana \|e verfasserin \|4 aut
700	0		\|a G. Orsolini \|e verfasserin \|4 aut
700	0		\|a E. Fracassi \|e verfasserin \|4 aut
700	0		\|a L. Idolazzi \|e verfasserin \|4 aut
700	0		\|a D. Gatti \|e verfasserin \|4 aut
700	0		\|a S. Adami \|e verfasserin \|4 aut
700	0		\|a M. Govoni \|e verfasserin \|4 aut
773	0	8	\|i In \|t Reumatismo \|d PAGEPress Publications, 2012 \|g 66(2015), 4, Seite 285-303 \|w (DE-627)355986361 \|w (DE-600)2091202-X \|x 22402683 \|7 nnns
773	1	8	\|g volume:66 \|g year:2015 \|g number:4 \|g pages:285-303
856	4	0	\|u https://doi.org/10.4081/reumatismo.2014.799 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/8d70cd031672426885f9e3dce692b8ee \|z kostenfrei
856	4	0	\|u http://www.reumatismo.org/index.php/reuma/article/view/799 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/0048-7449 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2240-2683 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 66 \|j 2015 \|e 4 \|h 285-303

Indexfelder

author_variant	m r mr o v ov g o go e f ef l i li d g dg s a sa m g mg
matchkey_str	article:22402683:2015----::hglmmbnhtetetfsraiatrtsnyoigpnyii
hierarchy_sort_str	2015
callnumber-subject-code	RC
publishDate	2015
allfields	10.4081/reumatismo.2014.799 doi (DE-627)DOAJ043830323 (DE-599)DOAJ8d70cd031672426885f9e3dce692b8ee DE-627 ger DE-627 rakwb eng ita RC31-1245 M. Rossini verfasserin aut Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis? 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis. Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis. Medicine R Internal medicine O Viapiana verfasserin aut G. Orsolini verfasserin aut E. Fracassi verfasserin aut L. Idolazzi verfasserin aut D. Gatti verfasserin aut S. Adami verfasserin aut M. Govoni verfasserin aut In Reumatismo PAGEPress Publications, 2012 66(2015), 4, Seite 285-303 (DE-627)355986361 (DE-600)2091202-X 22402683 nnns volume:66 year:2015 number:4 pages:285-303 https://doi.org/10.4081/reumatismo.2014.799 kostenfrei https://doaj.org/article/8d70cd031672426885f9e3dce692b8ee kostenfrei http://www.reumatismo.org/index.php/reuma/article/view/799 kostenfrei https://doaj.org/toc/0048-7449 Journal toc kostenfrei https://doaj.org/toc/2240-2683 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 66 2015 4 285-303
spelling	10.4081/reumatismo.2014.799 doi (DE-627)DOAJ043830323 (DE-599)DOAJ8d70cd031672426885f9e3dce692b8ee DE-627 ger DE-627 rakwb eng ita RC31-1245 M. Rossini verfasserin aut Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis? 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis. Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis. Medicine R Internal medicine O Viapiana verfasserin aut G. Orsolini verfasserin aut E. Fracassi verfasserin aut L. Idolazzi verfasserin aut D. Gatti verfasserin aut S. Adami verfasserin aut M. Govoni verfasserin aut In Reumatismo PAGEPress Publications, 2012 66(2015), 4, Seite 285-303 (DE-627)355986361 (DE-600)2091202-X 22402683 nnns volume:66 year:2015 number:4 pages:285-303 https://doi.org/10.4081/reumatismo.2014.799 kostenfrei https://doaj.org/article/8d70cd031672426885f9e3dce692b8ee kostenfrei http://www.reumatismo.org/index.php/reuma/article/view/799 kostenfrei https://doaj.org/toc/0048-7449 Journal toc kostenfrei https://doaj.org/toc/2240-2683 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 66 2015 4 285-303
allfields_unstemmed	10.4081/reumatismo.2014.799 doi (DE-627)DOAJ043830323 (DE-599)DOAJ8d70cd031672426885f9e3dce692b8ee DE-627 ger DE-627 rakwb eng ita RC31-1245 M. Rossini verfasserin aut Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis? 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis. Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis. Medicine R Internal medicine O Viapiana verfasserin aut G. Orsolini verfasserin aut E. Fracassi verfasserin aut L. Idolazzi verfasserin aut D. Gatti verfasserin aut S. Adami verfasserin aut M. Govoni verfasserin aut In Reumatismo PAGEPress Publications, 2012 66(2015), 4, Seite 285-303 (DE-627)355986361 (DE-600)2091202-X 22402683 nnns volume:66 year:2015 number:4 pages:285-303 https://doi.org/10.4081/reumatismo.2014.799 kostenfrei https://doaj.org/article/8d70cd031672426885f9e3dce692b8ee kostenfrei http://www.reumatismo.org/index.php/reuma/article/view/799 kostenfrei https://doaj.org/toc/0048-7449 Journal toc kostenfrei https://doaj.org/toc/2240-2683 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 66 2015 4 285-303
allfieldsGer	10.4081/reumatismo.2014.799 doi (DE-627)DOAJ043830323 (DE-599)DOAJ8d70cd031672426885f9e3dce692b8ee DE-627 ger DE-627 rakwb eng ita RC31-1245 M. Rossini verfasserin aut Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis? 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis. Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis. Medicine R Internal medicine O Viapiana verfasserin aut G. Orsolini verfasserin aut E. Fracassi verfasserin aut L. Idolazzi verfasserin aut D. Gatti verfasserin aut S. Adami verfasserin aut M. Govoni verfasserin aut In Reumatismo PAGEPress Publications, 2012 66(2015), 4, Seite 285-303 (DE-627)355986361 (DE-600)2091202-X 22402683 nnns volume:66 year:2015 number:4 pages:285-303 https://doi.org/10.4081/reumatismo.2014.799 kostenfrei https://doaj.org/article/8d70cd031672426885f9e3dce692b8ee kostenfrei http://www.reumatismo.org/index.php/reuma/article/view/799 kostenfrei https://doaj.org/toc/0048-7449 Journal toc kostenfrei https://doaj.org/toc/2240-2683 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 66 2015 4 285-303
allfieldsSound	10.4081/reumatismo.2014.799 doi (DE-627)DOAJ043830323 (DE-599)DOAJ8d70cd031672426885f9e3dce692b8ee DE-627 ger DE-627 rakwb eng ita RC31-1245 M. Rossini verfasserin aut Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis? 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis. Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis. Medicine R Internal medicine O Viapiana verfasserin aut G. Orsolini verfasserin aut E. Fracassi verfasserin aut L. Idolazzi verfasserin aut D. Gatti verfasserin aut S. Adami verfasserin aut M. Govoni verfasserin aut In Reumatismo PAGEPress Publications, 2012 66(2015), 4, Seite 285-303 (DE-627)355986361 (DE-600)2091202-X 22402683 nnns volume:66 year:2015 number:4 pages:285-303 https://doi.org/10.4081/reumatismo.2014.799 kostenfrei https://doaj.org/article/8d70cd031672426885f9e3dce692b8ee kostenfrei http://www.reumatismo.org/index.php/reuma/article/view/799 kostenfrei https://doaj.org/toc/0048-7449 Journal toc kostenfrei https://doaj.org/toc/2240-2683 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 66 2015 4 285-303
language	English Italian
source	In Reumatismo 66(2015), 4, Seite 285-303 volume:66 year:2015 number:4 pages:285-303
sourceStr	In Reumatismo 66(2015), 4, Seite 285-303 volume:66 year:2015 number:4 pages:285-303
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis. Medicine R Internal medicine
isfreeaccess_bool	true
container_title	Reumatismo
authorswithroles_txt_mv	M. Rossini @@aut@@ O Viapiana @@aut@@ G. Orsolini @@aut@@ E. Fracassi @@aut@@ L. Idolazzi @@aut@@ D. Gatti @@aut@@ S. Adami @@aut@@ M. Govoni @@aut@@
publishDateDaySort_date	2015-01-01T00:00:00Z
hierarchy_top_id	355986361
id	DOAJ043830323
language_de	englisch italienisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ043830323</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308074401.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2015 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.4081/reumatismo.2014.799</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ043830323</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ8d70cd031672426885f9e3dce692b8ee</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">ita</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC31-1245</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">M. Rossini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">O Viapiana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">G. Orsolini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. Fracassi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">L. Idolazzi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. Gatti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. Adami</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. Govoni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Reumatismo</subfield><subfield code="d">PAGEPress Publications, 2012</subfield><subfield code="g">66(2015), 4, Seite 285-303</subfield><subfield code="w">(DE-627)355986361</subfield><subfield code="w">(DE-600)2091202-X</subfield><subfield code="x">22402683</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:66</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:285-303</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.4081/reumatismo.2014.799</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/8d70cd031672426885f9e3dce692b8ee</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.reumatismo.org/index.php/reuma/article/view/799</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0048-7449</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2240-2683</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">66</subfield><subfield code="j">2015</subfield><subfield code="e">4</subfield><subfield code="h">285-303</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	M. Rossini
spellingShingle	M. Rossini misc RC31-1245 misc Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis. misc Medicine misc R misc Internal medicine Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
authorStr	M. Rossini
ppnlink_with_tag_str_mv	@@773@@(DE-627)355986361
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC31-1245
illustrated	Not Illustrated
issn	22402683
topic_title	RC31-1245 Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis? Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis
topic	misc RC31-1245 misc Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis. misc Medicine misc R misc Internal medicine
topic_unstemmed	misc RC31-1245 misc Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis. misc Medicine misc R misc Internal medicine
topic_browse	misc RC31-1245 misc Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis. misc Medicine misc R misc Internal medicine
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Reumatismo
hierarchy_parent_id	355986361
hierarchy_top_title	Reumatismo
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)355986361 (DE-600)2091202-X
title	Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
ctrlnum	(DE-627)DOAJ043830323 (DE-599)DOAJ8d70cd031672426885f9e3dce692b8ee
title_full	Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
author_sort	M. Rossini
journal	Reumatismo
journalStr	Reumatismo
callnumber-first-code	R
lang_code	eng ita
isOA_bool	true
recordtype	marc
publishDateSort	2015
contenttype_str_mv	txt
container_start_page	285
author_browse	M. Rossini O Viapiana G. Orsolini E. Fracassi L. Idolazzi D. Gatti S. Adami M. Govoni
container_volume	66
class	RC31-1245
format_se	Elektronische Aufsätze
author-letter	M. Rossini
doi_str_mv	10.4081/reumatismo.2014.799
author2-role	verfasserin
title_sort	why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
callnumber	RC31-1245
title_auth	Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
abstract	Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.
abstractGer	Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.
abstract_unstemmed	Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	4
title_short	Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
url	https://doi.org/10.4081/reumatismo.2014.799 https://doaj.org/article/8d70cd031672426885f9e3dce692b8ee http://www.reumatismo.org/index.php/reuma/article/view/799 https://doaj.org/toc/0048-7449 https://doaj.org/toc/2240-2683
remote_bool	true
author2	O Viapiana G. Orsolini E. Fracassi L. Idolazzi D. Gatti S. Adami M. Govoni
author2Str	O Viapiana G. Orsolini E. Fracassi L. Idolazzi D. Gatti S. Adami M. Govoni
ppnlink	355986361
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.4081/reumatismo.2014.799
callnumber-a	RC31-1245
up_date	2024-07-03T19:42:48.186Z
_version_	1803588225667694592
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ043830323</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308074401.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2015 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.4081/reumatismo.2014.799</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ043830323</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ8d70cd031672426885f9e3dce692b8ee</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">ita</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC31-1245</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">M. Rossini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">O Viapiana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">G. Orsolini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E. Fracassi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">L. Idolazzi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D. Gatti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. Adami</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. Govoni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Reumatismo</subfield><subfield code="d">PAGEPress Publications, 2012</subfield><subfield code="g">66(2015), 4, Seite 285-303</subfield><subfield code="w">(DE-627)355986361</subfield><subfield code="w">(DE-600)2091202-X</subfield><subfield code="x">22402683</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:66</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:285-303</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.4081/reumatismo.2014.799</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/8d70cd031672426885f9e3dce692b8ee</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.reumatismo.org/index.php/reuma/article/view/799</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0048-7449</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2240-2683</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">66</subfield><subfield code="j">2015</subfield><subfield code="e">4</subfield><subfield code="h">285-303</subfield></datafield></record></collection>
score	7.402895

Nicht das Richtige dabei?

Schreiben Sie uns!

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?